Thelansis

 Desmoid tumor (DT) is a rare type of monoclonal, fibroblastic proliferation that can have an unpredictable clinical course. The World Health Organization (WHO) classifies DT as a "clonal fibroblastic proliferation that arises in the deep soft tissues and is characterized by infiltrative growth and a tendency toward local recurrence but an inability to metastasize." While DT can occur in multiple areas of the same limb or body part, it typically appears in abdominal, intra-abdominal, and extra-abdominal locations. About 5-10% of DT cases occur in individuals with familial adenomatous polyposis (FAP). CTNNB1 mutations and APC mutations are mutually exclusive in DT. Diagnosis depends on a combination of morphologic and immunohistochemical findings. DT is most often poorly circumscribed on a surgical specimen, featuring a scar-like, whitish-cut surface and ranging in size. Microscopically, a DT is composed of a cytologically bland, at most moderately cellular, infiltrative spind...

 A desmoid tumor (DT) is a rare monoclonal, fibroblastic proliferation characterized by a variable and often unpredictable clinical course. DT is a “clonal fibroblastic proliferation that arises in the deep soft tissues and is characterized by infiltrative growth and a tendency toward local recurrence but an inability to metastasize,” even though it may be multifocal in the same limb or body part. It may occur at abdominal, intra-abdominal, and extra-abdominal locations, and approximately 5% to 10% arise in the context of familial adenomatous polyposis (FAP). ·        Desmoid tumor incidence ranges from 5 to 7.5 cases per million population in the USA. Thelansis’s “Desmoid Tumor Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptak...